Back to Search Start Over

Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment

Authors :
Zulma M, Cucunubá
Pierre, Nouvellet
Jennifer K, Peterson
Sarah M, Bartsch
Bruce Y, Lee
Andrew P, Dobson
Maria-Gloria, Basáñez
Source :
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Publication Year :
2018

Abstract

Background The World Health Organization’s 2020 goals for Chagas disease are (1) interrupting vector-borne intradomiciliary transmission and (2) having all infected people under care in endemic countries. Insecticide spraying has proved efficacious for reaching the first goal, but active transmission remains in several regions. For the second, treatment has mostly been restricted to recently infected patients, who comprise only a small proportion of all infected individuals. Methods We extended our previous dynamic transmission model to simulate a domestic Chagas disease transmission cycle and examined the effects of both vector control and etiological treatment on achieving the operational criterion proposed by the Pan American Health Organization for intradomiciliary, vectorial transmission interruption (ie, 30 years (high endemicity). When this strategy is combined with annual etiological treatment in 10% of the infected human population, the seroprevalence criterion would be achieved, respectively, in 1 and 11 years. Conclusions Combining highly effective vector control with etiological (trypanocidal) treatment in humans would substantially reduce time to transmission interruption as well as infection incidence and prevalence. However, the success of vector control may depend on prevailing vector species. It will be crucial to improve the coverage of screening programs, the performance of diagnostic tests, the proportion of people treated, and the efficacy of trypanocidal drugs. While screening and access can be incremented as part of strengthening the health systems response, improving diagnostics performance and drug efficacy will require further research.

Details

ISSN :
15376591
Volume :
66
Issue :
suppl_4
Database :
OpenAIRE
Journal :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Accession number :
edsair.pmid..........4b0929bd1f66ef9e60bebcb1a8776abb